Ask AI

Advancing Care in Essential Thrombocythemia and Polycythemia Vera: Prognostic Tools, Patient-Centered Care, and Emerging Therapies

Enhance your ability to integrate the latest evidence and evolving treatment strategies into the individualized management of polycythemia vera and essential thrombocythemia. Explore strategies for applying contemporary prognostic models, including MIPSS and the Triple A score, incorporating longitudinal molecular profiling into risk stratification and treatment planning, engaging patients in shared decision-making, and evaluating emerging clinical trial data and investigational therapies, including LSD1 inhibitors, to optimize patient outcomes.

Share

Program Content

Activities

LSD1 inhibition in PV and ET
LSD1 Inhibition in Polycythemia Vera and Essential Thrombocythemia
Video
Congratulations: You achieved a completion on 04/09/2022

Released: November 19, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

Supporters

This activity is supported by an educational grant from Merck Sharp & Dohme LLC.

Merck Sharp & Dohme LLC